X0306 4 2021-01-31 0 0001438533 Travere Therapeutics, Inc. TVTX 0001698262 ROTE WILLIAM E. C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, STE 300 SAN DIEGO CA 92130 0 1 0 0 Senior Vice President, R&D Common Stock 2021-01-31 4 A 0 5000 0.00 A 44582 D Common Stock 2021-02-02 4 S 0 2500 30.75 D 40957 D Common Stock 2021-02-02 4 S 0 1125 30.75 D 43457 D On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study. The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. /s/ Elizabeth E. Reed, Attorney-in-Fact 2021-02-02